{
    "clinical_study": {
        "@rank": "24947", 
        "arm_group": {
            "arm_group_label": "PEG-Formulation", 
            "arm_group_type": "Experimental", 
            "description": "PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is therefore to investigate the efficacy of the PEG-formulation to\n      reduce the frequency and duration of genital herpes recurrences, to assess its safety and\n      tolerability and to investigate its effect on shedding."
        }, 
        "brief_title": "A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Genital Herpes", 
        "condition_browse": {
            "mesh_term": "Herpes Genitalis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed Consent\n\n          -  18 - 65 years\n\n          -  Positive for HSV-1 and/or -2 (as determined by serology testing in course of study)\n\n          -  Initial infection > 1 year ago\n\n          -  \u2265 6 recurrences in the last year (or in the year prior to a recent prophylactic\n             therapy)\n\n          -  \u2265 2 recurrences during the six-month baseline period\n\n        Exclusion Criteria:\n\n          -  Known or suspected allergy or intolerability to PEG\n\n          -  Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs\n             and steroids within less than 14 days prior to baseline period, or plan to take such\n             drugs during the trial\n\n          -  Pregnancy and/or breast-feeding\n\n          -  History of malignant diseases (described in chapter 7.2)\n\n          -  Known or suspected non-compliance to study protocol\n\n          -  Participation in another investigational drug study in the last 30 days prior to\n             baseline period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765114", 
            "org_study_id": "DEV-PEG-02"
        }, 
        "intervention": {
            "arm_group_label": "PEG-Formulation", 
            "intervention_name": "PEG-Formulation", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich"
            }, 
            "investigator": {
                "last_name": "Thomas Kuendig, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes", 
        "other_outcome": {
            "measure": "The frequency of days with viral shedding which will be analysed by quantitative PCR.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Treatment period (6 months each)."
        }, 
        "overall_contact": {
            "email": "thomas.kuendig@usz.ch", 
            "last_name": "Thomas Kuendig, MD", 
            "phone": "+41 (0)44 255 39 73"
        }, 
        "overall_contact_backup": {
            "email": "fabian.tay@usz.ch", 
            "last_name": "Fabian Tay, MD", 
            "phone": "+41 (0)44 255 11 11"
        }, 
        "overall_official": {
            "affiliation": "University of Zurich", 
            "last_name": "Thomas Kuendig, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of genital herpes recurrences will be counted during the baseline period (6 months) and during the treatment period (6 months) and then be compared.", 
            "measure": "Change of number of genital herpes recurrences during the treatment period as compared to the baseline period.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Treatment period (6 months each)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The safety of the PEG-formulation via reporting of AEs.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and Treatment period (6 months each)."
        }, 
        "source": "Devirex AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Devirex AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}